Overview

Natalizumab and Chronic Inflammation

Status:
Not yet recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

In this study the investigators will assess the ability of Natalizumab, a medication given to treat multiple sclerosis (MS), to restore blood brain barrier integrity and repair subtle leakages of the blood brain barrier (BBB).

Phase:

Phase 4

Details

Lead Sponsor:

Vanderbilt University Medical Center

Collaborator:

Biogen

Treatments:

Natalizumab